Literature DB >> 15117088

Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction.

C Stief1, H Porst, I Sáenz De Tejada, E Ulbrich, M Beneke.   

Abstract

This randomised, double-blind study assessed the long-term efficacy and tolerability of vardenafil 10 and 20 mg in men with erectile dysfunction (ED). A total of 566 men who completed an initial 12-month treatment period entered a 12-month extension. In these men, both doses of vardenafil produced improvement in scores for the 'erectile function' Domain of the International Index of Erectile Function, evident from week 4 and maintained through 2 years. Sexual Encounter Profile diary responses indicated that following treatment, penetration was achieved on 92-94% of attempts and erections that lasted long enough for successful intercourse were achieved on 87-89% of attempts. In response to the General Assessment Question, 90-92% of patients reported improved erections with vardenafil. Most treatment-emergent events were mild and transient with no cardiovascular safety concerns. These results support the long-term efficacy, reliability and tolerability of vardenafil 10 and 20 mg in men with ED.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117088     DOI: 10.1111/j.1368-5031.2004.00128.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  11 in total

1.  Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials.

Authors:  Roland Heinig; Boris Weimann; Hartmut Dietrich; Michael-Friedrich Böttcher
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Alberto Briganti; Andrea Salonia; Federico Deho'; Giuseppe Zanni; Luigi Barbieri; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

3.  Effect of levitra on sustenance of erection (EROS): an open-label, prospective, multicenter, single-arm study to investigate erection duration measured by stopwatch with flexible dose vardenafil administered for 8 weeks in subjects with erectile dysfunction.

Authors:  Y S Shin; S W Lee; K Park; W S Chung; S W Kim; J S Hyun; D G Moon; S-K Yang; J K Ryu; D Y Yang; K H Moon; K S Min; J K Park
Journal:  Int J Impot Res       Date:  2014-12-04       Impact factor: 2.896

Review 4.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

6.  Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.

Authors:  Ferdinando Fusco; Riccardo Sicuteri; Andrea Rossi; Stathis Kontodimas; Jose Maria Haro; Ciro Imbimbo; Vincenzo Mirone
Journal:  Asian J Androl       Date:  2009-08-24       Impact factor: 3.285

7.  Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II.

Authors:  Luc Valiquette; Francesco Montorsi; Stephen Auerbach
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 8.  Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.

Authors:  Andrew McCullough
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

Review 9.  Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  BMC Urol       Date:  2005-12-14       Impact factor: 2.264

10.  REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome.

Authors:  Ridwan Shabsigh; Andreas Mattern
Journal:  Sex Med       Date:  2016-04-14       Impact factor: 2.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.